Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma

Bayer20 enrolled

Overview

This is an observational study which will investigate the use of Nexavar as first targeted therapy in patients with advanced renal cell carcinoma.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Carcinoma, Renal Cell

Interventions

Sorafenib (Nexavar, BAY 43-9006)DRUG

Dosage according to label or at discretion of the attending physician

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with a diagnosis of advanced Renal cell carcinoma (RCC) for whom the decision has been taken by the investigator to prescribe Nexavar. * Patients who failed cytokine therapy or who are not suitable for cytokines for whom Nexavar is the first targeted drug treatment. Exclusion Criteria: * Prior targeted therapy for RCC * Contraindications of Nexavar described in the Summary of Product Characteristics (SPC).

Locations (1)

Unnamed facility

Many Locations, Germany

Outcomes

Primary Outcomes

Duration of Nexavar treatment

Time frame: up to 3 years

Secondary Outcomes

Overall Survival (OS)

Time frame: 1 - 1.5 years after LPLV

Health related quality of life (HRQoL)

Time frame: up to 3 years

Progression-free survival (PFS)

Time frame: up to 3 years

Tumor status, of patients will be evaluated according to the categories "Complete Response", "Partial Response", "Stable Disease", "Clinical Progression", "Radiological Progression".

Time frame: up to 3 years

Incidence of Treatment-emergent Adverse Events (TEAE)

Time frame: up to 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.